Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir, Cisplatin, and Radiation for Locally Advanced Vulvar Cancer
NCT04169763Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nelfinavir in vulvar cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Recommended Phase II Dose at 1 year and Incidence of Adverse Events at 1 year. Started Aug 2020; status: recruiting.
02
Drugs
nelfinavir
03
Conditions
vulvar cancer
Beyond the preview
Go deeper on NCT04169763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169763.